Articles related to Pathology

Patients whose disease has progressed on osimertinib or other EGFR tyrosine kinase inhibitors (TKIs) without emergent T790M or other targetable alterations can receive platinum-based chemotherapy with or without amivantamab.

The emergence of novel agents including BTK degraders, next-generation BCL2 inhibitors, and optimized combination approaches is reshaping the CLL treatment landscape, with multiple trials demonstrating high uMRD rates, improved progression-free survival, and manageable toxicity profiles across different patient populations.

Flow cytometric evaluation of MRD in AML demonstrates that blast phenotypes consistently show abnormalities but may evolve during treatment, emphasizing the importance of comprehensive antigen panel analysis for accurate detection.

“Having achieved a complete pathologic response was the best-case scenario that we could have hoped for.”

Early cancer detection through AI-analyzed blood tests could lead to personalized mRNA vaccine production in just 48 hours, according to Oracle CEO Larry Ellison.

Although genomic classifier tests for prostate cancer show promise, a systematic review of 22 studies reveals marked differences between observational and trial data in how these tests influence risk stratification and treatment selection.